Biotechnology company Celyad Oncology (Euronext Brussels:CYAD) announced on Thursday that it has sold its C-Cathez transendocardial catheter to CellProthera, including all intellectual property rights and technical documentation.
The catheter will serve as a core component in CellProthera's upcoming Phase 3 clinical trial, enabling targeted stem cell delivery to damaged cardiac tissue.
The agreement provides for up to EUR5m in milestone-based payments and future royalties on net sales. As the consideration is fully deferred, the transaction will not affect Celyad Oncology's current cash runway, which is expected to last through the third quarter of 2026.
CellProthera is a regenerative cell therapy developer specializing in ischemic diseases, with a leading program in myocardial infarction.
GE HealthCare expands Vivid cardiovascular ultrasound portfolio with three new systems
Daiichi Sankyo data highlight real-world impact of bempedoic acid on cardiovascular risk
Revier Therapeutics closes EUR6m seed financing and launches operations
Tempus announces receipt of FDA clearance for AI pulmonary hypertension detection product
European Commission grants orphan designation for Lundbeck's asedebart
Hanmi Pharm enters exclusive licensing deal with Genentech for obesity therapy HM17321
PTC to acquire BLA-stage ST-920 Fabry disease programme
Olio Labs reveals study demonstrating AI-driven in vivo platform can predict clinical trial outcomes
Mezzion Pharma Co reports positive results from new in vivo study of udenafil
Incyte's Opzelura approved in European Union for moderate atopic dermatitis